CNS-selective 5-HT4 partial agonist, designed as a brain-penetrant successor to Prucalopride. Prucalopride was validated in healthy people across three independent tasks: RAVLT (verbal recall), PILT (probabilistic learning), and emotional memory recognition, all showing significant improvement (Murphy et al., 2020). problem was diarrhea from peripheral cAMP activity. Usmarapride fixes this with selective CNS penetration.
Mechanism: 5-HT4 agonism drives hippocampal cAMP, which triggers BDNF release, dendritic growth, and neurogenesis. Also reduces hippocampal excitability and blocks depotentiation, raising the Long Term Potentiation encoding threshold while protecting established traces. The pro-cognitive effect is hippocampus-specific: Prucalopride showed no effect on working memory or implicit contextual learning, which are PFC-dependent tasks (Murphy et al., 2020). For full cognitive coverage pair with Tropisetron, Neboglamine, an M1 ligand, or TAK-653.
new context changed a few things, 5-HT4 agonists increase cortical Acetylcholine and histamine, potentiate donepezil-induced ACh release, and increase hippocampal theta power. The dentate-gyrus finding is also very on-theme: 5-HT4 partial agonism prevents depotentiation, so the effect is less “more memory now” and more “freshly encoded traces are harder to dissolve.”
The hippocampal excitability reduction is the anxiolytic mechanism. Hippocampal neurogenesis accounts for the antidepressant effects. synergy; Usmarapride drives hippocampal BDNF release, ACD-856 sensitizes TrkB for it. Mechanistically tight and subjectively strong. Phase 1 class-level data from SUVN-D4010 (same 5-HT4 agonist class): generally safe, with relatively high headache occurrence above 15mg (Nirogi et al., 2021). Hard ceiling there.
stress-resilience angle: prucalopride / PF-04995274 / RS67333 data suggests 5-HT4 partial agonism can act prophylactically against learned fear and stress-induced depressive behavior, with p11 as a relevant 5-HT4 trafficking/signaling cofactor (stress prophylaxis review).
Bibliography
- Murphy, S. E., Wright, L. C., Browning, M., Cowen, P. J., & Harmer, C. J. (2020). A Role for 5-HT4 Receptors in Human Learning and Memory. Psychological Medicine, 50(16), 2722–2730. https://doi.org/10.1017/S0033291719002836
- Nirogi, R., Bhyrapuneni, G., Muddana, N. R., Goyal, V. K., Pandey, S. K., Mohammed, A. R., Ravula, J., Jetta, S., & Palacharla, V. R. C. (2021). First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects. Clinical Drug Investigation, 41(5), 469–482. https://doi.org/10.1007/s40261-021-01027-4